MA50096A - Formulations de nanoparticules lipidiques de vecteurs d'adn exempts de capside non viraux - Google Patents

Formulations de nanoparticules lipidiques de vecteurs d'adn exempts de capside non viraux

Info

Publication number
MA50096A
MA50096A MA050096A MA50096A MA50096A MA 50096 A MA50096 A MA 50096A MA 050096 A MA050096 A MA 050096A MA 50096 A MA50096 A MA 50096A MA 50096 A MA50096 A MA 50096A
Authority
MA
Morocco
Prior art keywords
free dna
lipid nanoparticle
dna vectors
nanoparticle formulations
viral capside
Prior art date
Application number
MA050096A
Other languages
English (en)
Inventor
Ozan Alkan
Douglas Anthony Kerr
Robert Michael Kotin
Ara Karl Malakian
Matthew John Simmons
Matthew G Stanton
Jie Su
Teresa L Wright
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of MA50096A publication Critical patent/MA50096A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
MA050096A 2017-09-08 2018-09-07 Formulations de nanoparticules lipidiques de vecteurs d'adn exempts de capside non viraux MA50096A (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762556334P 2017-09-08 2017-09-08
US201762556333P 2017-09-08 2017-09-08
US201762556381P 2017-09-09 2017-09-09
US201862675327P 2018-05-23 2018-05-23
US201862675317P 2018-05-23 2018-05-23
US201862675322P 2018-05-23 2018-05-23
US201862675324P 2018-05-23 2018-05-23

Publications (1)

Publication Number Publication Date
MA50096A true MA50096A (fr) 2020-07-15

Family

ID=65635269

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050096A MA50096A (fr) 2017-09-08 2018-09-07 Formulations de nanoparticules lipidiques de vecteurs d'adn exempts de capside non viraux

Country Status (15)

Country Link
US (1) US20210059953A1 (fr)
EP (1) EP3679148A4 (fr)
JP (2) JP2020537493A (fr)
KR (1) KR20200051708A (fr)
CN (1) CN111295448A (fr)
AU (1) AU2018330208A1 (fr)
BR (1) BR112020004219A2 (fr)
CA (1) CA3075180A1 (fr)
CO (1) CO2020002262A2 (fr)
IL (1) IL272799A (fr)
MA (1) MA50096A (fr)
MX (1) MX2020002501A (fr)
PH (1) PH12020500466A1 (fr)
SG (1) SG11202000765PA (fr)
WO (1) WO2019051289A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020016288A2 (pt) * 2018-02-14 2020-12-15 Generation Bio Co. Vetores de dna não virais e usos dos mesmos para produção de anticorpos e proteínas de fusão
WO2019226650A1 (fr) * 2018-05-23 2019-11-28 Modernatx, Inc. Administration d'adn
WO2021016075A1 (fr) 2019-07-19 2021-01-28 Flagship Pioneering Innovations Vi, Llc Compositions à recombinase et leurs méthodes d'utilisation
WO2021030312A1 (fr) * 2019-08-12 2021-02-18 Generation Bio Co. Méthodes et compositions pour réduire des réponses immunitaires associées à une thérapie génique ou d'acide nucléique
CN114929205A (zh) * 2019-09-06 2022-08-19 世代生物公司 包括末端封闭式dna和可切割脂质的脂质纳米颗粒组合物及其使用方法
WO2021102411A1 (fr) * 2019-11-22 2021-05-27 Generation Bio Co. Lipides ionisables et compositions de nanoparticules associées
CN110974954B (zh) * 2019-12-24 2021-03-16 珠海丽凡达生物技术有限公司 一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法
WO2021236930A1 (fr) 2020-05-20 2021-11-25 Flagship Pioneering Innovations Vi, Llc Compositions immunogènes et leurs utilisations
CA3179420A1 (fr) 2020-05-20 2021-11-25 Avak Kahvejian Compositions d'antigenes de coronavirus et leurs utilisations
EP4158031A1 (fr) 2020-05-29 2023-04-05 Flagship Pioneering Innovations VI, LLC Compositions de trem et procédés associés
EP4158032A2 (fr) 2020-05-29 2023-04-05 Flagship Pioneering Innovations VI, LLC Compositions à base de trem et procédés associés
JP2023535632A (ja) 2020-07-27 2023-08-18 アンジャリウム バイオサイエンシズ エージー Ｄｎａ分子の組成物、その作製方法、及びその使用方法
AU2021336976A1 (en) 2020-09-03 2023-03-23 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
GB202014751D0 (en) 2020-09-18 2020-11-04 Lightbio Ltd Targeting vector
AU2021385572A1 (en) 2020-11-25 2023-06-22 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
WO2022140702A1 (fr) 2020-12-23 2022-06-30 Flagship Pioneering, Inc. Compositions de molécules effectrices à base d'arnt (trem) modifiées et leurs utilisations
WO2022155195A1 (fr) * 2021-01-12 2022-07-21 Peranteau William Nanoparticules de lipide ionisables destinées à l'administration in utéro d'arnm
CA3214085A1 (fr) 2021-03-31 2022-10-06 Darby Rye Schmidt Polypeptides de thanotransmission et leur utilisation dans le traitement du cancer
WO2023009547A1 (fr) 2021-07-26 2023-02-02 Flagship Pioneering Innovations Vi, Llc Compositions de trem et leurs utilisations
EP4124348A1 (fr) * 2021-07-30 2023-02-01 4basebio UK Ltd Nanoparticules pour l'administration de cellules
EP4271818A1 (fr) 2021-09-17 2023-11-08 Flagship Pioneering Innovations VI, LLC Compositions et procédés de production de polyribonucléotides circulaires
TW202322826A (zh) 2021-10-18 2023-06-16 美商旗艦先鋒創新有限責任公司 用於純化多核糖核苷酸之組成物及方法
WO2023096990A1 (fr) 2021-11-24 2023-06-01 Flagship Pioneering Innovation Vi, Llc Compositions immunogènes de coronavirus et leurs utilisations
WO2023097003A2 (fr) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Compositions immunogènes et leurs utilisations
WO2023096963A1 (fr) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Compositions d'immunogènes du virus varicelle-zona et leurs utilisations
AR128002A1 (es) 2021-12-17 2024-03-20 Flagship Pioneering Innovations Vi Llc Métodos de enriquecimiento de rna circular en condiciones desnaturalizantes
TW202340461A (zh) 2021-12-22 2023-10-16 美商旗艦先鋒創新有限責任公司 用於純化多核糖核苷酸之組成物和方法
WO2023122789A1 (fr) 2021-12-23 2023-06-29 Flagship Pioneering Innovations Vi, Llc Polyribonucléotides circulaires codant pour des polypeptides antifusogènes
WO2023148303A1 (fr) * 2022-02-02 2023-08-10 Mslsolutions Gmbh Procédé de production de médicaments et de vaccins
WO2023177655A1 (fr) * 2022-03-14 2023-09-21 Generation Bio Co. Compositions vaccinales prime-boost hétérologues et méthodes d'utilisation
WO2023183616A1 (fr) 2022-03-25 2023-09-28 Senda Biosciences, Inc. Nouveaux lipides et nanoparticules lipidiques ionisables et leurs procédés d'utilisation
WO2023196185A1 (fr) * 2022-04-04 2023-10-12 Spark Therapeutics, Inc. Amélioration immunitaire et traitement de maladies infectieuses
WO2023196634A2 (fr) 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccins et procédés associés
WO2023220083A1 (fr) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc Compositions de trem et procédés d'utilisation pour traiter des troubles prolifératifs
WO2023220729A2 (fr) 2022-05-13 2023-11-16 Flagship Pioneering Innovations Vii, Llc Compositions d'adn à double brin et procédés associés
WO2023250112A1 (fr) 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Compositions de trem modifiées et leurs utilisations
WO2024015428A1 (fr) * 2022-07-12 2024-01-18 Trustees Of Boston University Voies de signalisation cellulaire synthétiques et leurs utilisations
WO2024030856A2 (fr) 2022-08-01 2024-02-08 Flagship Pioneering Innovations Vii, Llc Protéines immunomodulatrices et méthodes associées
KR102544632B1 (ko) * 2022-08-05 2023-06-16 주식회사 무진메디 장쇄 세라마이드가 포함된 지질 나노입자 및 이를 포함하는 세포 사멸용 조성물
WO2024035952A1 (fr) 2022-08-12 2024-02-15 Remix Therapeutics Inc. Procédés et compositions pour moduler l'épissage au niveau de sites d'épissage alternatifs
WO2024049979A2 (fr) 2022-08-31 2024-03-07 Senda Biosciences, Inc. Nouveaux lipides ionisables et nanoparticules lipidiques, ainsi que procédés d'utilisation associés
WO2024077191A1 (fr) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) * 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5869305A (en) * 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
DE10044384A1 (de) * 2000-09-08 2002-04-18 Medigene Ag Wirtszellen zur Verpackung von rekombinantem Adeno-assoziiertem Virus (rAAV), Verfahren zu ihrer Herstellung und deren Verwendung
JP2008526229A (ja) * 2005-01-06 2008-07-24 ベニテック，インコーポレーテッド 幹細胞の維持のためのＲＮＡｉ剤
EP2816118B1 (fr) * 2005-05-31 2018-10-17 The Regents of the University of Colorado, a body corporate Procédés pour administrer des gènes
EP1979485A2 (fr) * 2006-01-31 2008-10-15 The Board Of Trustees Of The Leland Stanford Junior University Vecteurs parvoviraux auto-complémentaires et leurs procédés de fabrication et d'utilisation
AU2016203992A1 (en) * 2009-05-11 2016-06-30 Berg Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
EP2500434A1 (fr) * 2011-03-12 2012-09-19 Association Institut de Myologie Vecteurs AAV sans capside, compositions et procédés pour la production des vecteurs et la thérapie génique
US9943574B2 (en) * 2012-06-27 2018-04-17 Arthrogen B.V. Combination for treating an inflammatory disorder
AU2013355258A1 (en) * 2012-12-07 2015-06-11 Alnylam Pharmaceuticals, Inc. Improved nucleic acid lipid particle formulations
PL2968586T3 (pl) * 2013-03-14 2019-01-31 Translate Bio, Inc. Kompozycje mrna cftr i związne z nimi sposoby i zastosowania
CA2917018A1 (fr) * 2013-05-21 2014-12-04 University Of Florida Research Foundation, Inc. Compositions de vecteur raav3 a modification capsidique et procedes d'utilisation dans la therapie genetique du cancer du foie humain
EP4019506A1 (fr) * 2013-12-19 2022-06-29 Novartis AG Lipides et compositions lipidiques pour l'administration d'agents actifs
WO2016110518A1 (fr) * 2015-01-07 2016-07-14 Universitat Autònoma De Barcelona Construction génique à vecteur unique comprenant des gènes d'insuline et de glucokinase
US11046955B2 (en) * 2015-04-24 2021-06-29 University Of Massachusetts Modified AAV constructs and uses thereof
AU2016377681B2 (en) * 2015-12-22 2021-05-13 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
RU2752882C2 (ru) * 2016-03-03 2021-08-11 Юниверсити Оф Массачусетс Линейная дуплексная днк с закрытым концом для невирусного переноса генов

Also Published As

Publication number Publication date
BR112020004219A2 (pt) 2020-09-08
IL272799A (en) 2020-04-30
KR20200051708A (ko) 2020-05-13
JP2020537493A (ja) 2020-12-24
MX2020002501A (es) 2020-09-17
JP2023002828A (ja) 2023-01-10
AU2018330208A1 (en) 2020-02-27
US20210059953A1 (en) 2021-03-04
CN111295448A (zh) 2020-06-16
CA3075180A1 (fr) 2019-03-14
RU2020110805A3 (fr) 2022-01-19
PH12020500466A1 (en) 2021-01-25
EP3679148A1 (fr) 2020-07-15
CO2020002262A2 (es) 2020-05-29
EP3679148A4 (fr) 2021-06-09
WO2019051289A1 (fr) 2019-03-14
SG11202000765PA (en) 2020-03-30
WO2019051289A9 (fr) 2019-06-20
RU2020110805A (ru) 2021-10-11

Similar Documents

Publication Publication Date Title
MA50096A (fr) Formulations de nanoparticules lipidiques de vecteurs d'adn exempts de capside non viraux
MA49421A (fr) Formulations d'arn
IL286515A (en) Novel lipids and nanoparticle formulations of lipids for delivery of nucleic acids
HK1249015A1 (zh) 布魯頓氏酪氨酸激酶抑制劑的醫藥配方
MA46466A (fr) Formulations pharmaceutiques de protéines à viscosité réduite
MA41937A (fr) Conjugués de médicaments comprenant des anticorps contre la claudine 18.2
IL263709A (en) Methods for the manufacture of cannabinoid prodrugs, pharmaceutical formulations and their use
IL261700A (en) Formulations and dosages of oricase modified in polyethylene glycol
EP3286321A4 (fr) Vecteur de virus adéno-associé pour le traitement de l'ataxie de friedreich
IL259468A (en) The reference to formyl peptide receptor 2/lipoxin receptor 4a (fpr2/alx) for the treatment of heart disease
MA45478A (fr) Compositions de conjugués d'acides nucléiques ciblés
MA55219A (fr) Nanoparticules lipidiques non actives avec adn dépourvu de capside, non viral
MA55015A (fr) Formulations pharmaceutiques
MA52644A (fr) Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
MA50670A (fr) Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose
ITUB20153542A1 (it) Composizione cosmetica ad attivita' idratante
MA45451A (fr) Formulations tensioactives destinées à l'inhalation
IL254252A0 (en) History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease
IT201700084036A1 (it) Formulazioni di prodotti per la colorazione dei capelli.
MA49148A (fr) Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
WO2018094035A3 (fr) Conjugués ligand-ionophore
FR3037336B1 (fr) Composes derives de l'acide 3-(alkylthio)propenoique, et leur application en cosmetique
PL3697914T3 (pl) Wektory do leczenia ataksji friedreicha
MA47234A (fr) Immunoconjugués ciblant l'adam9 et leurs méthodes d'utilisation
TR201714474A2 (tr) BMN 673 (Talazoparib) Yüklü Katı Lipid Nanopartikül (KLN) Formülasyonu